Publications
Product
Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications (cPMTb)
Int J Mol Sci. 20(17):4274 / 2019.08 [LINK]
Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4 (cPMTb)
Drug Metab Pharmacokinet.34(3):201-208 / 2019.06 [LINK]
Inhibition of cytochrome P450 activities by Sophora flavescens extract and its prenylated flavonoids in human liver microsomes (cPMTb)
Evid Based Complement Alternat Med. 13:2019:2673769 / 2019.03 [LINK]
10-Phenyltriazoyl artemisinin is a novel P-glycoprotein inhibitor that suppresses the overexpression and function of P-glycoprotein. (cPMTb)
Curr Pharm Des. 24(46):5590-5597 / 2019.02 [LINK]
Identification and characterization of amiodarone metabolites in rats using UPLC-ESI-QTOFMS-based untargeted metabolomics approach (cPMTb)
J Toxicol Environ Health A. 81(12):481-492 / 2018.05 [LINK]
Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) (cPMTb)
Prostaglandins Leukot Essent Fatty Acids. 131:6-13 / 2018.04 [LINK]
Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets. (BMRC, PRCDM)
Prostaglandins Leukot Essent Fatty Acids. 89(4):227-34 / 2013.09 [LINK]
2013-International
Single nucleotide polymorphisms in SULT1A1 and SULT1A2 in a Korean population. (BMRC, PRCDM)
Drug Metab Pharmacokinet. 28(4):372-7 / 2013.05 [LINK]
2013-International
·
Lee SJ.
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. (BMRC, PRCDM)
Front Genet. 3:318 / 2013.02 [LINK]
2013-International
Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4. (BMRC)
Drug Metab Dispos. 41(8):1529-37 / 2013.08 [LINK]
2013-International 
